Topical Umbilical Cord Care for Prevention of Infection and Neonatal Mortality

Jamlick Karumbi, BPharm,* †‡ Mercy Mulaku, BPharm, †‡ Jalemba Aluvaala, MMed,* †‡§ Mike English, PhD, † ‡ Mike and Newton Opiyo, MSc†

Abstract: Umbilical cord care varies often reflecting community or health-worker beliefs. We undertook a review of current evidence on topical umbilical cord care. Study quality was assessed using the Grading of Recommendations, Assessment, Development and Evaluation system, and a meta-analysis was conducted for comparable trials. Available moderate-quality to high-quality evidence indicate that cord cleansing with 4% chlorhexidine may reduce the risk of neonatal mortality and sepsis (omphalitis) in low-resource settings.

Key Words: cord care, chlorhexidine, neonatal mortality, sepsis, neonates (Pediatr Infect Dis J 2013;32: 78–83)

Annually about 3.3 million neonatal deaths occur around the world, of which more than 30% are caused by infections. Some of these infections start as umbilical cord infection. The umbilical cord area supports growth of some innocuous or beneficial microorganisms (commensals) whereas others are harmful (eg, Clostridium tetani). Sources of these bacteria include the mother’s birth canal, the environment in which the neonate is delivered and hands of the person assisting with the delivery. Cord infection may be localized to the umbilical cord (omphalitis) or, after entry into the blood stream, become systemic (eg, neonatal sepsis). The incidence of omphalitis in low-income countries is generally scarce, the available data estimate the risk to range between 2 and 77 per 1000 live births in hospital settings, with fatality rates of between 1% and 15% depending on the definition of omphalitis used. Community-based data show even higher infection rates; for example, 105 per 1000 live births in Nepal, 217 per 1000 live births in Pakistan and about 197 per 1000 live births in India. Remarkably, no data are currently available from most countries in Africa where most deliveries still occur at home and where neonatal mortality remains high. Two trials on the effect of 4% chlorhexidine (CHX) on neonatal mortality and umbilical cord infections are, however, ongoing in Zanzibar and Zambia.

As cord infections should be preventable in most cases, it is important to identify best cord care practices to reduce neonatal mortality and morbidity and offer an alternative to widespread potentially harmful traditional practices. Examples of such practices include the use of traditional herbs mixed with cooking oil or water that has been used to wash an adult woman’s genitals (numbati) or application of ash, breast milk, fluid from pumpkin flowers, powder ground from local trees, cow dung, ghee and saliva that may be applied to the cord area and which may be harmful.

Internationally, the World Health Organization has advocated since 1998 for the use of dry umbilical cord care (keeping the cord clean without application of anything and leaving it exposed to air or loosely covered by a clean cloth, in case it becomes soiled it is only cleaned with water). World Health Organization recommends topical antiseptics (eg, CHX) in situations where hygienic conditions are poor and/or infection rates are high. However, a Cochrane review published in July 2004 found no benefit on neonatal mortality or rates of disseminated or localized infection of applying antiseptics or antibiotics to the cord stump compared with dry cord care. The findings of this Cochrane review may, however, not be generalizable to the African setting, as most of the included studies (19/21) were from high-income countries and all but 1 were conducted in hospital settings.

In Kenya, clinical guidelines recommend dry cord care, however, anecdotal evidence and experience suggest that health care providers vary in their practice, for example, using alcohol, methylated spirit or povidone iodine to clean the cord. To help Kenyan policy makers develop appropriate national guidance, we conducted a review to define safe and effective topical umbilical cord care for prevention of mortality and cord infections in newborn infants.

METHODS

Search Strategy

Potential studies for inclusion in the review were identified through direct searches on the Cochrane Library and PubMed. The search terms used were “umbilical cord” OR “umbilical” OR “umbilicus” AND “neonate” OR “newborn” OR “infant” AND “anti-bacterial agent” OR “anti-infective agent” OR “anti-sepsis agent” OR “antimicrobial agent” OR “antiseptic”. PubMed clinical query filters for systematic reviews and randomized controlled trials (RCTs) were applied. We searched for studies published between January 2003 and February 2012 (spanning the period not included in the Cochrane review published in July 2004). Bibliographic references of retrieved reviews and studies were searched for additional articles. The searches were limited to studies published in English due to time constraints.

Study Selection Criteria

RCTs and cluster-RCTs (cRCTs) that compared different topical agents versus dry cord care, different cord cleansing

Accepted for publication August 15, 2012.

From the *Division of Paediatrics, Ministry of Medical Services, Afya House; †SIRCLE Collaboration, KEMRI-Wellcome Trust Research Programme; ‡School of Pharmacy; §Department of Paediatrics, University of Nairobi, Nairobi, Kenya; and †Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

ME conceived the idea for the review. JK and MM conducted the literature searches, NO, JA and JK screened the records for eligibility. NO and JK assessed the quality and synthesized the results. JK drafted the final review. All the authors reviewed and approved the final draft.

JK, MM and JA were supported by funds from the SIRCLE Collaboration. ME was supported by a Wellcome Trust Senior Fellowship (0970827). NO was supported by funds from a Wellcome Trust Strategic Award (#084538). The funding source had no role in the conduct of the review and writing of the report. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Jamlick Karumbi, BPharm, SIRCLE Collaboration, KEMRI-Wellcome Trust Research Programme, P.O. Box 43640, Nairobi 00100, Kenya. E-mail: jkarumbi@nairobi.kemri-wellcome.org.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Data Extraction

Data on study characteristics (study design, settings), participants, nature of interventions, proportion of participants with events of interest (eg, death or infection of the cord stump) and outcome measures were extracted and entered into a standardized form. The abstraction was done by 1 reviewer; a second reviewer counter checked the extracted data. Disagreements were resolved by consensus.

Data Synthesis

For the studies published after the Cochrane review, we summarized results narratively for a subset of hospital-based studies where interventions and outcomes varied significantly. However, for 3 cRCTs, a random-effects meta-analysis (studies had some heterogeneity) was used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for mortality outcomes. $\chi^2$ test of heterogeneity and I² statistic were used to assess and quantify heterogeneity.

Quality Appraisal

The quality of the available evidence about the prespecified outcomes to support a given intervention was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The GRADE approach classifies evidence quality into 4 categories: high, moderate, low or very low. The unique features of GRADE include: (1) explicit, comprehensive criteria for downgrading and upgrading quality of evidence ratings; (2) explicit evaluation of the importance of outcomes; and (3) clear separation of quality of evidence from the strength of recommendations. Results of the quality assessments are summarized and presented using GRADE summary-of-findings tables. Two reviewers independently assessed study quality; disagreements were resolved by discussion. Studies were not excluded based on their quality rating but outcomes of quality assessments were taken into account in the synthesis of results.

RESULTS

Forty-four potentially relevant articles were identified from the literature searches. Eight studies and 2 systematic reviews were deemed eligible for inclusion (Fig., Supplemental Digital Content 1, http://links.lww.com/INF/B375). Study settings varied; 3 studies were conducted in low-income countries, 2 in middle-income countries and 3 in high-income countries. The interventions used included 4% CHX, olive oil, triple dye, breast milk, alcohol and silver sulfadiazine (antibiotic) whereas the comparisons included dry cord care and salicylic sugar (Table, Supplemental Digital Content 2, http://links.lww.com/INF/B376). Quality of evidence for the reported outcomes varied from (low to high; Tables 1–3).

Systematic Reviews

One Cochrane review published in July 2004 summarized the findings of 21 hospital studies (13 RCTs and 8 quasi-RCTs; N = 8959). Nineteen of the studies were conducted in high-income countries, and only 2 were from low-resource countries. Overall, the review concluded that topical cord care with the various agents (antiseptics, antibiotics or even traditional substances) was not superior to air drying of the cord for the outcomes of mortality or systemic infections originating from the cord. None of the reviewed studies included any fatal events or episodes of severe sepsis. However, the reviewers acknowledged that the results of the primary studies were not generalizable to the global newborn population as there were few (2 of 21; n = 699 newborns) studies from low-resource settings. The GRADE approach was, however, not used to assess the quality of evidence in this review.

### TABLE 1. Summary-of-findings Table on Mortality and Omphalitis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative Comparative Risks</th>
<th>Relative Effect (95% CI)</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed Risk</td>
<td>Corresponding Risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dry Care</td>
<td>Antimicrobials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonatal mortality number of deaths within 28 d</td>
<td>26 per 1000</td>
<td>23 per 1000 (21–26)</td>
<td>RR 0.88 (0.79–0.99)</td>
<td>44,818 (3 studies)</td>
<td>$\oplus\oplus\oplus$ high*</td>
</tr>
<tr>
<td>Follow-up: mean 28 d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omphalitis number of omphalitis cases</td>
<td>108 per 1000</td>
<td>84 per 1000 (81–88)</td>
<td>RR 0.78 (0.75–0.81)</td>
<td>44,600 (3 studies)</td>
<td>$\oplus\oplus\oplus$ moderate*</td>
</tr>
<tr>
<td>Follow-up: mean 28 d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Antimicrobials compared with dry care for umbilical cord care.

Patient or population: patients with umbilical cord care

Settings: community

Intervention: antimicrobials

Comparison: dry care

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

*Study setting: Asia.
TABLE 2. Summary-of-findings Table on Sepsis and Omphalitis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks</th>
<th>Results</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed Risk</td>
<td>Corresponding Risk</td>
<td>No. of Participants (studies)</td>
<td>Low</td>
</tr>
<tr>
<td>Dry Care/Other Antimicrobials</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td>822 (4 studies)</td>
<td>† † † †</td>
</tr>
<tr>
<td>Antimicrobial Agent</td>
<td>Use of antimicrobials has no effect on cord infection in the hospital setting</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Antimicrobial agent compared with dry care/other antimicrobials for umbilical cord care.
Patient or population: newborn babies
Settings: hospital
Intervention: antimicrobial agent
Comparison: dry care/other antimicrobials
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 All sample sizes less than 350; all studies were hospital based.
2 One study (Pezzati et al, 2003) compared a powder vs. a solution hence blinding was not possible.
3 All the studies used different interventions ranging, including olive oil, salicylic powder, alcohol, breast milk.
4 Study settings: hospital setting in middle-income and high-income countries.

TABLE 3. Summary-of-findings on Umbilical Cord Separation Time (UCST)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks</th>
<th>Results</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umbilical cord separation time (time in days)</td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td>No. of Participants (studies)</td>
<td>Low</td>
</tr>
<tr>
<td>Dry care</td>
<td>Not estimable</td>
<td>The mean umbilical cord separation time in the intervention group ranged from 4 to 17 higher</td>
<td>25,256 (5 studies)</td>
<td>† †</td>
</tr>
<tr>
<td>Antimicrobial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Antimicrobial use in umbilical cord care
Patient or population: newborn babies
Settings: both community and hospital
Intervention: antimicrobial
Comparison: dry care
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Study settings: cluster-RCTs were in low-income countries community setting whereas the 3 small RCTs were in middle-income and high-income countries.
2 Two studies were huge cluster-RCTs (N = 24,628) whereas the other 3 were small RCTs (N = 628).

The non-Cochrane review published in November 2003 examined the use of antimicrobial agents to reduce bacterial colonization and local infection (omphalitis) in newborn infants. Eighteen studies (10 RCTs and 8 observational designs) enrolling a total of 39,635 newborns were included. None of the studies reported mortality among the participants. Ten studies had infection as an outcome (3 RCTs, n = 3540 and 7 observational studies, n = 32,057): 2 of the RCTs (n = 2774) and 3 observational studies (n = 7704) found 4% CHX to be associated with decreased rates of infections. The remaining studies compared alternative topical antimicrobials or topical antimicrobials with dry cord care and reported no significant difference in infection rates (both local and systemic). Overall, the authors concluded that in areas with high infection rates cord antisepsis (particularly 4% CHX) has the potential to reduce the risk of neonatal sepsis and death (although none of the included studies reported any deaths). They also acknowledged that antimicrobials reduced colonization but there has been no evidence to show that increased colonization of the umbilical stump leads to infections.

Randomized Controlled Trials

The results of 5 hospital-based and 3 community-based trials published after the included Cochrane review are summarized below.

Effects of 4% Chlorhexidine on Neonatal Mortality. Four studies assessed this outcome. Three of these studies were community-based cRCTs and 1 was a hospital-based RCT. The 3 high-quality cRCTs (n = 44,818) used 4% CHX as the intervention compared with dry care (Table 1). Meta-analysis of these 3 studies showed that 4% CHX, compared with dry care, was
associated with a 17% reduction in the risk of neonatal mortality (pooled RR 0.83, 95% CI: 0.74–0.94, F = 0%; Fig. 1). Arifeen et al18 (n = 29,760) also compared the effect of single 4% CHX application (as soon as possible after birth) and multiple CHX cleansing (daily cleansing for 7 days after birth) to dry cord care. Neonatal mortality was significantly reduced in the single CHX cleansing group compared with the dry cord care group (RR 0.80, 95% CI: 0.65–0.98). No differences in neonatal mortality were found between multiple CHX cleansing and dry cord care groups (RR 0.94, 95% CI: 0.78–1.14). The hospital-based study22 (n = 244) compared the effects of 4% CHX and salicylic sugar powder on mortality; no mortality was reported in either of the comparison groups.

Effects on Neonatal Sepsis and Omphalitis. Omphalitis was defined as severe redness and pus in 2 studies17,19 and any redness and pus in 1 study.2 The hospital-based studies17,19–21,23 had no clear definition of omphalitis.

This outcome was reported by 3 community and 5 hospital studies (N = 55,334). Moderate quality evidence (Table 1) from the 3 community-based studies suggests a reduction in omphalitis and sepsis with the use of 4% CHX. Soofi et al18 (n = 9741) reported a reduction of omphalitis in the CHX cleansing group (RR 0.44, 95% CI: 0.29–0.67) whereas Mullany et al18 (n = 14,887) reported a reduction by 32–75% depending on the definition of the omphalitis (severe redness and pus: RR 0.25, 95% CI: 0.12–0.53; pus and moderate or severe redness or severe redness alone: RR 0.46, 95% CI: 0.36–0.56; redness extending to base of umbilicus: RR 0.68, 95% CI: 0.58–0.80). This reduction of severe omphalitis was even greater if the intervention was within 24 hours of birth (incidence rate ratio 0.13, 95% CI: 0.07–0.31). Arifeen et al18 (n = 29,760) reported a reduction in severe infection (redness with pus) in the multiple CHX cleansing group (RR 0.35, 95% CI: 0.15–0.81) and a lesser reduction in the single CHX cleansing group (RR 0.77, 95% CI: 0.40–1.48).

Low-quality evidence from small hospital-based studies17,19–21,23 (N = 946) suggests that use of antimicrobials has no effect on cord infection (Table 2). Pezzati et al21 (Italy, n = 244) compared 4% CHX with salicylic sugar powder in preterm babies but reported only 1 case of sepsis in each arm, whereas Ahmadpour et al17 (Iran, n = 312), Erenel et al19 (Turkey, n = 150), Hsu et al20 (Taiwan, n = 150) and Suliman et al22 (United States, n = 90) reported no or very few cases of omphalitis or sepsis when newborns were randomized to cord care approaches including breast milk, 96% alcohol, silver sulfadiazine, triple dye, olive oil or dry cord care.

**DISCUSSION**

High-quality evidence from 3 community cRCTs, in rural areas of low-income countries, enrolling about 44,000 newborns suggests that the use of 4% CHX reduces neonatal mortality in community settings, more so if this intervention is used in regions where infection rates are high. Although data are from Asia, such settings are likely similar to several sub-Saharan countries including Kenya, where home delivery is common and infection rates probably high. Use of 4% CHX was found to be more effective if offered within the first 24 hours, and it seems that even a single application is effective. This may be explained by the activity of CHX, an antiseptic that has a long duration of action and is broad spectrum.11 In contrast, hospital-based trials that were generally much smaller with low event rates provide low-quality evidence and did not report any effect of antimicrobials on mortality.

The heterogeneous nature of the data on sepsis/omphalitis outcomes made it inappropriate to combine the results in a meta-analysis (F = 91%, Fig. 2). The causes of this heterogeneity were explored and included differences in: the frequency of CHX applications, definitions of infections (omphalitis) and study designs. However, there was moderate quality evidence suggesting that 4% CHX greatly reduces morbidity especially when started within 24 hours of birth in community settings and low-quality evidence (Table 2) suggesting that applying an antimicrobial is no better than leaving the cord to dry when in the high-income or middle-income hospital setting. The apparent consistent evidence of effect, at least in community settings, of 4% CHX contrasts with the mixed effects noted when it has been used by application to the mother’s birth canal or more widely to the skin surface of neonates.25,26

Low-quality evidence (Table 3) suggests that application of a powder formulation reduces the time to cord separation. This is consistent with other studies not included in this review27–29 that report that powder formulations reduce cord separation time, attributed to a drying effect, although they may lead to cord bleeding. These findings may be of relevance in selecting CHX formulation if health workers and families prefer more rapid cord separation.

In addition to considering the effectiveness of CHX, its safety is important when wide-scale use is proposed. Fortunately, CHX is felt to be generally safe to use as despite extensive use in medical settings since the 1950s, only isolated adverse events...
such as contact sensitivity, dermatitis, urticaria and photosensitivity have been reported. There have been specific, extensive studies of the safety of CHX in newborns. Although reports have documented percutaneous absorption of CHX when used as a body wash or for cord care, no adverse clinical consequences have been reported. This absorption is, however, likely to occur when CHX is used on premature and underweight newborns. None of the 3 cRCTs recorded any severe adverse event further supporting CHX’s safety profile.

There are some limitations to our study. First, we searched only a limited number of databases, with a focus on English language publications, but our review included data on a large number of newborns (N = 54,000). Second, none of the studies so far reported are from African countries making downgrading of the quality of evidence on the basis of indirectness a consideration from a Kenyan perspective. Sparser, lower quality data suffering more obviously from limitations of indirectness were challenges when considering CHX use for facility-based births. For a country such as Kenya, where omphalitis and severe infection in facility-born babies may still be common, arguably data from both community and facility settings should be used to inform discussions on recommendations. Finally, application of other potentially harmful substances in the dry cord care group may have confounded group comparisons.

Based on the high-quality evidence from the included studies, it seems reasonable to include 4% CHX for topical cord care as a package of care for clean deliveries for newborn infants both in the community and hospital settings in Kenya and similar countries in anticipation of positive results from studies already under way in Zambia and Zambia. Such studies are expected to provide additional information on the frequency of application. Although CHX is itself relatively cheap (the cost is about $9 per 5 liters in Kenya), thought will need to be given to the logistics of delivering such an intervention routinely in countries where at least half of all births occur at home in the absence of a skilled attendant. Logistic considerations will benefit from research on optimal formulations (such as gels or powders rather than liquids), delivery channels and professional and public education to stimulate demand and promote uptake of CHX.

Based on the available moderate-quality to high-quality evidence, we conclude that the use of 4% CHX can be beneficial in reducing neonatal mortality and morbidity among infants born at home in countries such as Kenya. For infants born in hospitals, only low-quality evidence largely from high-income settings currently exists and shows no benefit of using any topical substance including CHX over dry cord care. Given that babies born in facilities in low-income African settings have moderately high risks of severe infection and to promote development of a consistent, systemwide policy, it seems reasonable to consider using 4% CHX for all births in Kenya. More research is needed on the optimal mode of CHX delivery to support its use at scale.

### FIGURE 2. Comparison: 4% chlorhexidine versus dry cord care, outcome: neonatal sepsis and omphalitis.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>4% Chlorhexidine</th>
<th>Dry cord care</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Sorf 2012</td>
<td>84</td>
<td>2053</td>
<td>162</td>
<td>2399</td>
</tr>
<tr>
<td>Mullany 2006</td>
<td>598</td>
<td>4334</td>
<td>1005</td>
<td>5982</td>
</tr>
<tr>
<td>Ariffen 2012</td>
<td>1044</td>
<td>19088</td>
<td>703</td>
<td>9264</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>27195</td>
<td>14705</td>
<td>17405</td>
<td>100%</td>
</tr>
<tr>
<td>Total events</td>
<td>1726</td>
<td>1890</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>Tau² = 0.04; CHF = 22.66, df = 2 (P &lt; 0.0001); P = 91%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall</td>
<td>Z = 4.23 (P &lt; 0.0001)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**REFERENCES**


